-
-
Out of curiosity, how does RNAseqPower compare to Scotty when the same pilot data is used for both? Regardless, that's a nice tool to have! -
I hadn't actually seen it before, but it is a very good looking web app! The power estimates should be similar, but won't be identical for 2 reasons:
1. Scotty assumes that variance follows a lognormal distribution. I think this is a valid and logical assumption. RNASeqPower uses the measured variance from the data instead.
2. Scotty pseudo-randomly selects 200 values from a 2 dimensional matrix (variance and depth) then uses that mean as the power of the dataset. The way we use RNASeqPower is to say that we want to know the minimum requirements to reach the desired power. We need to know two things, how many genes do I want to detect and how much variance to I want to allow. If you only want to detect the top 90% of genes, then you take the 10th percentile of gene counts for your pilot (all other genes will have more than this count). You do the same for variance except you select the 90th percentile of variance. Using the minimum read count and the maximum allowable variance, that is the power you have in your experiment. Granted most genes will have higher power since they will have lower variance and higher counts. So in the end, it comes down to how you define what power actually means.
RNASeqPower can also give you the power for each gene in a dataset.Comment
-
Cool, thanks!Comment
Tweet
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment